Boise, Idaho-based Burst Biologics will begin a study involving spinal fusion patients.
Here are five things to know:
1. The study will enroll 450 patients at 15 clinical sites throughout the U.S.
2. BioBurst Fluid, a cellular allograft found in umbilical cord blood, will be used in the study. The fluid has exhibited promising results in spinal fusion procedures.
3. Currently valued at $1.6 billion, the global spine biologics market is expected to reach $2.2 billion by 2022 and represents a significant opportunity for innovative biologic products.
4. Patients with poor health or low healing recovery would benefit most from successful studies investigating cellular content’s impact on spinal fusion.
5. Burst Biologics CEO Chris Jones said, “An open registry allows us to evaluate success rates in complex cases that would otherwise be excluded from studies… We want to demonstrate to spine surgeons and third-party payers that BioBurst Fluid can be successful in their more challenging patients.”
More articles on devices:
Integra expands Cadence Total Ankle System — 5 notes